Abstract
Deferasirox is a new iron chelator approved recently for chelation therapy in iron-overloaded patients. It is considered safe and efficacious in most patients, but has not been tested formally in patients with end-stage renal disease. We report a case of a patient with end-stage renal disease secondary to sickle cell nephropathy who developed recurrent symptomatic hypocalcemia while on therapy and later reexposure with this medication for iron overload from long-term blood transfusions. This is the first case report of this complication with deferasirox therapy in a patient with end-stage renal disease.
MeSH terms
-
Adult
-
Anemia, Sickle Cell / complications
-
Anemia, Sickle Cell / therapy
-
Benzoates / adverse effects*
-
Benzoates / therapeutic use
-
Deferasirox
-
Erythropoietin / therapeutic use
-
Female
-
Humans
-
Hypertension / complications
-
Hypocalcemia / chemically induced*
-
Iron Chelating Agents / adverse effects*
-
Iron Chelating Agents / therapeutic use
-
Iron Overload / drug therapy*
-
Iron Overload / etiology
-
Kidney Failure, Chronic / etiology
-
Kidney Failure, Chronic / therapy
-
Peritoneal Dialysis / adverse effects*
-
Transfusion Reaction
-
Triazoles / adverse effects*
-
Triazoles / therapeutic use
Substances
-
Benzoates
-
Iron Chelating Agents
-
Triazoles
-
Erythropoietin
-
Deferasirox